What is Smart Stock Agent?

Smart Stock Agent is an AI-powered analysis platform for US stock market traders, covering equities listed on the NYSE and Nasdaq. It provides trade strategies, ROI calculations, technical analysis, Sharia compliance screening, earnings forecasts, and real-time market data to help investors make informed decisions.

Which stock markets does Smart Stock Agent cover?

Smart Stock Agent focuses on the US stock market, covering equities listed on the NYSE and Nasdaq, including S&P 500, Dow Jones, and Nasdaq-100 companies. All trade timing recommendations are aligned with US regular market hours (9:30 AM - 4:00 PM Eastern Time).

How does the AI stock analysis work?

Our AI analyzes multiple data points including company financials, technical indicators, market trends, earnings data, and news sentiment to generate comprehensive stock analysis with trade strategies, entry/exit points, risk assessments, and ROI projections.

What is Sharia compliance screening?

Sharia compliance screening evaluates stocks against Islamic investment principles based on AAOIFI Standard 21. It checks business activities, debt ratios, interest income, and other financial metrics to determine if a stock is Halal (permissible) or Haram (prohibited) for Islamic investors.

What trade strategies does Smart Stock Agent provide?

Smart Stock Agent provides detailed trade strategies including tranche-based entry plans, exit price targets, stop-loss levels, ROI calculations, and optimal timing recommendations based on technical analysis and market conditions.

Is Smart Stock Agent free to use?

Smart Stock Agent offers comprehensive stock analysis tools. Sign up for free to access basic features, with premium options available for advanced analysis and unlimited stock searches.

How accurate are the AI predictions?

Our AI uses advanced machine learning models trained on historical market data and current market conditions. While we strive for high accuracy, all investments carry risk, and our analysis should be used as one of many tools in your investment decision-making process.

ABBV

NYSE

AbbVie Inc.

$253.86

Healthcare · Drug Manufacturers - General

ABBV Key Statistics

Market Cap

$449.08B

P/E Ratio

124.63

EPS (TTM)

2.05

52-Week High

$254.7

52-Week Low

$181.75

Analyst Target

$261.86

About AbbVie Inc.

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Get the full AI-powered analysis for ABBV

Sign in to unlock AI trade strategies, entry/exit timing in US Eastern Time, ROI projections, technical indicators (RSI, MACD, Bollinger Bands), earnings forecasts, and Sharia compliance screening.

Get Started Free

Other Popular US Stocks

AAPL MSFT NVDA AVGO ORCL AMD CRM MU QCOM TXN ADBE INTC

Disclaimer: This application does not guarantee investment results. Use at your own risk. The information provided is for educational purposes only and should not be considered as financial advice.